Washington, DC – August 6, 2024 – Cooley advised Blue Owl Capital (NYSE: OWL), a top asset manager that is redefining alternatives, and HealthCare Royalty (HCRx), a top royalty acquisition company focused on commercial or near-commercial biopharmaceutical products, on a $250 million term loan facility with TG Therapeutics (NASDAQ: TGTX), a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.
Lawyers Michael Tollini, Mischi a Marca and Addison Pierce led the interdisciplinary Cooley team advising Blue Owl and HCRx, which also included life sciences partner Geoffrey Spolyar, patent counseling and prosecution partner Jon Cousin, and tax partner Xander Lee.
Cooley previously advised Blue Owl on its up to $1.05 billion investment in BridgeBio Pharma in January 2024 and its up to $140 million investment in XOMA Corporation in December 2023.
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,300+ lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.